Glial cell line-derived neurotrophic factor (GDNF) was assayed for its neurotrophic effects against the neuronal atrophy that causes cognitive deficits in old age. Aged Fisher 344 rats with impairment in the Morris water maze received intrahippocampal injections at the dorsal CA1 area of either a lentiviral vector encoding human GDNF or the same vector encoding human green fluorescent protein as a control. Recombinant lentiviral vectors constructed with human cytomegalovirus promotor and pseudotyped with lyssavirus Mokola glycoprotein specifically transduced the astrocytes in vivo. Astrocyte-secreted GDNF enhanced neuron function as shown by local increases in synthesis of the neurotransmitters acetylcholine, dopamine and serotonin. This neurotrophic effect led to cognitive improvement of the rats as early as two weeks after gene transduction. Spatial learning and memory testing showed a significant gain in cognitive abilities due to GDNF exposure, whereas control-transduced rats kept their performance at the chance level. These results confirm the broad spectrum of the neurotrophic action of GDNF and open new gene therapy possibilities for reducing age-related neurodegeneration.
Introduction
Glial cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth factor superfamily. It was first isolated from culture medium of rat B49 glioblastoma cells in a search of trophic factors for midbrain dopaminergic neurons [73, 74] . GDNF has remarkable regenerative and restorative effects upon nigrostriatal dopaminergic neurons [16, 46, 51] . Soon after its discovery, it was found that GDNF is a potent neurotrophic factor active on a broad spectrum of neuronal types and has neuroprotective effects in several experimental paradigms of nerve cell injury. For instance, GDNF reduces neuronal damage in axotomized neurons [56, 96, 121, 126] , in experimental brain trauma [7] and ischemia [23, 64, 87, 122] , and in several excitotoxic [78, 92, 100, 124] and neurotoxic injuries modeling neurodegenerative diseases [6, 50, 119] . Therapeutic GDNF administration has raised expectations that it could be a preventive or palliative treatment for Parkinson's disease [for review see: 35, 38] , amyotrophic lateral sclerosis [for review see : 12,82 
] and
Huntington's disease [for review see : 3] .
GDNF is expressed in both neurons and astrocytes [73, 77, 92, 108] . It signals through the two-component receptor complex GFR -/Ret [118] , also expressed in both cell types [92] . An increase in astrocyte GDNF synthesis and protein expression is believed to play an active role in neuron survival and plasticity after ischemia [88, 117] and excitotoxic damage [60, 77] . Accordingly, experimental strategies of GDNF delivery by astrocytes have shown to be neuroprotective in vivo for motor neurons [97, 128] and dopaminergic neurons [29, 31, 34] .
Endogenous GDNF plays an important role in cognitive abilities as demonstrated by the impaired spatial learning performance of mice that are heterozygous for a targeted deletion of the GDNF gene [49] . Spatial learning and memory is associated with intact hippocampus function and it has long been known that memory deficits in old age are similar to those produced by bilateral hippocampal lesions [18, 52] . Different categories of agents, such as neurotrophins [40, 41, 79] , antioxidant agents [72, 94] and cholinergic drugs [13, 58] , have been assayed in aged rodents in a search for effective and harmless treatments that reverse the memory loss of normal aging and ameliorate memory loss in pathological aging caused by Alzheimer's disease. The potential of GDNF against age-related cognitive deterioration has not been fully explored. In a previous study, spatial learning and memory improved in aged rats after i.c.v. administration of GDNF but no brain regional correlates were analyzed [99] . We studied the restorative effects of GDNF on spatial learning and memory after local delivery into the hippocampus. For this purpose, the astrocytes of the dorsal CA1 hippocampal area of cognitively impaired aged Fisher 344 rats were transduced in vivo with a lentiviral vector expressing the human gene for GDNF. The efficacy of transgene delivery, either GDNF or the human green fluorescent protein (GFP) used as a control, and the behavioral and neurotransmitter changes shown by the aged rats were determined throughout the study. Brain regional GDNF gene expression allowed the evaluation of the involvement of the hippocampal CA1 function in maintaining spatial learning and memory through aging. Vector specificity for the GDNF gene transfer to astrocytes enabled the study of the neuroprotective potential of these glial cells in neurodegenerative processes.
Methods

Animal groups
Thirty male 7-month old Fisher 344 rats retired from breeding were purchased from Charles River (Lyon, France) and kept in the animal house of the University of Barcelona until they were old. They were maintained in standard conditions of temperature and humidity, with two animals per cage, a 12:12 h light-dark cycle, and food and water ad libitum. Only animals showing a healthy general status at 22 months of age were included in the study. A group of 10 young male rats of the same origin were used to test the viral stock. A further group of 10 6-month old male Fisher 344 rats were included in the study for comparative neurotransmitter determinations. All handling and experimental procedures were approved by the Animal Ethics and Health Committees of the University of Barcelona.
Lentiviral vectors
A recombinant lentiviral vector encoding human GDNF was constructed for the specific transduction of astrocytes in vivo. The combination of the lyssavirus Mokola glycoprotein (Mokola G) pseudotype with the human cytomegalovirus promoter (CMV) allowed efficient transgene expression under these experimental conditions. A vector encoding GFP instead of GDNF was used as a control vector. Vectors were constructed and produced as previously described [10, 91] . Briefly, the plasmids Flap-CMV-GDNF-WPRE and Flap-CMV-GFP-WPRE were derived from the lentiviral vector genome. These plasmids contain the backbone of the lentiviral genome including the central Flap sequence [127] . The GDNF and GFP transgenes were under control of the CMV promoter. The woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was added 3 to the GDNF or GFP gene to increase transgene expression [129] . Lentiviral vector stocks were produced by transient co-transfection of 293T cells with the vector genome plasmid, a packaging plasmid and a plasmid coding for the envelope that included the Mokola G gene. The cell supernatant for each transgene vector was harvested 48 h post-transfection, treated with DNase, filtered through 0.45 µm pore-sized filters, and subjected to ultra-centrifugation at 64,000 x g for 90 min. The virus pellet was resuspended in phosphate-buffered saline (PBS) and its physical titer was quantified by ELISA of the p24 capsid protein. Viral stocks were kept at -80ºC until use. At that moment, stocks were diluted with PBS to 30 ng/ l of p24 protein.
Behavioral testing
The behavioral test for spatial learning and memory was performed in a Morris water maze [89] . The apparatus was modeled as described elsewhere [22] . Briefly, it measured 1.60 m in diameter and water was made opaque by the addition of 100 mL/L of latex. Water temperature was maintained at 22±1ºC. Black curtains surrounded the pool. Inside the black enclosure four landmarks hanging from a false black ceiling defined the position of the hidden platform: A, a 40-W fixed light; B, a beach ball with horizontal color drawings; C, a vertical white structure with three truncated cones of decreasing size; and D, three silver bottles bound by their neck. Landmark objects were hung at 90º distance. The platform has a diameter of 0.11 m and was placed between landmarks A and B, 1 cm below the surface and 0.38 m from the side. The landmarks and the platform were semi-randomly rotated with respect to the room (90º, 180º, 270º, 360º) in a daily-equated way in order to ensure that the rats used these landmarks, rather than any inadvertently remaining static room cue, to locate the platform. A closed-circuit video camera recorded rat movements that were analyzed by computer. A pre-training test with the platform made visible, located 1 cm above the water surface, consisted of 8 trials during 2 days. The rat was given 90 s to find the platform, and then allowed to stay on for 30 s. When the rat did not reach the platform, it was picked up, placed on it and left there for 30 s. Rats that failed to find the visible platform were discarded from the study. For the acquisition test, the procedure was the same, but animals had to rely on the landmarks to find the hidden platform. Animals were given 4 escape trials per day for 12 days, a total of 48 trials. Latencies to reach the escape platform were recorded for each trial and averaged for the 4 daily trials. On the last day, a 60 s probe trial was performed with the platform removed. To analyze the rat's behavior, the surface of the pool was divided into four quadrants and the time that the rat spent in the quadrant where the platform was previously was calculated. Impaired aged rats were defined as those spending a time not different from chance performance (15 s out of 60 s) in the right quadrant during the spatial probe trial. Two weeks later, the impaired animals were divided in two groups that were treated for hippocampal astrocyte expression of GFP and GDNF, respectively (see surgical procedures below). Test assays were initiated two weeks after surgery, when rats were nearly 24 months old. Animals were given 4 escape trials per day and on the fourth day a probe trial was performed. This procedure continued, with a probe trial every four days until 48 escape trials had been conducted.
Behavioral results for rats that did not survive until the end of the study were not included.
Surgical procedures
A total of 23 aged rats underwent surgery: 7 rats of the GFP group, 8 rats of the GDNF group and 8 unimpaired rats. Animals were anesthetized with 10 mg/kg xylacine (Rompun 2%, Bayer) and 80 mg/kg ketamine (Ketolar 50 mg/ml, Pfizer) i.m., and placed in a stereotactic apparatus. Bilateral infusions were performed into the CA1 area of the hippocampus at the coordinates: anterior-posterior -3.8 mm, medio-lateral +/-2 mm and dorso-ventral -2.4 mm, from bregma and dural surface. The right coordinates to reach were previously checked in 3 animals discarded from the study. One l of the vector solution was delivered to the application point with a 25-gauge stainless steal cannula (Small Parts 
Brain dissection and histology
After completion of the behavioral studies, animals were decapitated under light anesthesia with 40 mg/kg ketamine. Brains were quickly removed, immersed in cold saline solution and placed in a Kopf brain blocker. The cerebrum was cut into three blocks and then bisected sagittaly at the midline. A block containing the half dorsal hippocampal area of selected animals from the GFP group was fixed by immersion in 10% phosphate buffered formaldehyde, cryoprotected with 10% sucrose and frozen on a stainless steel plate over dry ice. Slices 16 m thin were double-stained with the antibodies against GFP 1:1000 (polyclonal, Abcam, Cambridge, UK) and GFAP 1:400 (monoclonal, clone GA5, Sigma, St. Louis, MO), as previously described [10] . Secondary antibodies used were Alexa Fluor 488 1:1000 and Alexa Fluor 546 1:1000, respectively (Molecular Probes, Eugene, OR).
Nuclei were counterstained with bisbenzimide (Sigma). For all other animals, both hemispheres were further dissected on a chilled glass plate, according to the procedure described in detail elsewhere [8] . Tissue samples for 6 hippocampal areas (dorsal and ventral CA1, dorsal and ventral CA2/3, dorsal and ventral dentate gyrus), 5 cerebral cortical areas (cingulate, frontal, temporal, entorhinal, parietal), septum and caudate [98] , were weighed and frozen at -80ºC until analysis.
GDNF determination
The level of GDNF expression of the viral stock under the injection conditions used was tested in a group of 10 young rats of the same colony used for the experiment. A microinjection of the GDNF vector was performed in the dorsal CA1 area of the right hippocampus as described above. GFP vector was injected on the left side of half the animals and the other half were untreated. Rats were killed a week later, and the hippocampus dissected as described above. Regional tissue levels of GDNF were determined by ELISA with the GDNF E max ImmunoAssay System kit (Promega), following the manufacturer's instructions. Long-term stability of this viral stock was previously checked and expression was stable for one year (unpublished data).
Choline acetyl transferase and monoamine neurotransmitter determinations
Choline acetyl transferase (ChAT) activity in the tissue samples was measured by the formation of 14 [C]acetylcholine from 14 [C]acetylcoenzyme-A (60 mCi/mmol; New England Nuclear, PerkinElmer, Wellesley, MA) and choline (Sigma). For this purpose, homogenates from left cerebral hemisphere regions were processed following the procedure described elsewhere [5] .
The monoamine neurotransmitters, dopamine and serotonin, the acid metabolites of adjusted with phosphoric acid), and 18 % methanol. Both mobile phases were pumped at 0.7 mL/min. Quantitative analyses were performed by the external standard method.
Statistics
Results are expressed as mean ± SEM. Statistical evaluation was performed with ANOVA procedures, followed by Bonferroni's or Newman-Keules's multi-range test for comparison of the mean group values.
Results
Astrocyte transduction with GFP and GDNF
The injection of lentiviral particles aimed at the dorsal CA1 hippocampal area yielded a wide GFP expression mainly in the stratum radiatum and also in the oriens layer of this area. No expression was detected beyond the hippocampus. Transduced proteins were selectively expressed in astrocytes as demonstrated by overlapping of GFP and GFAP immunostaining whereas no GFP expression was detected in the neurons of the pyramidal molecular layer (GFP transduced rats, Fig. 1a-g ). In a parallel study, we have confirmed the astrocyte specific expression of the GFP reporter gene with the presently used vector in several animal species (mouse, rat and non-human primate; Brizard et al., unpublished observations).
The ability of the GDNF-engineered lentiviral vector to drive a detectable production of GDNF was previously confirmed in a separate group of animals. GDNF levels determined by ELISA were higher in the dorsal CA1 transduced with GDNF than in the GFPtransduced or untreated CA1 area of the contralateral side (Table 1) . A lesser GDNF overexpression was detected in the ipsilateral adjacent area CA2/3.
Improved performance of GDNF injected rats in the Morris water maze
Timing of the behavioral studies is indicated in Fig. 2a . The aged animals were clearly classified as non-impaired or learning-impaired, according to the results of the pre-test spatial probe trial (Fig. 2b, probe trial 0) . Non-impaired rats spent 27.8 ± 3.6 s (n=8) and impaired rats spent 15.5 ± 4.3 s (n=15) out of the 60 s in the pool quadrant that previously contained the platform (p<0.0001 and p=0.6746 as against to chance value of 15 s, respectively). During prior training, latencies to find the hidden escape platform decreased steadily without significant group differences (two-way ANOVA, effect of day factor: F(11,211)=4.915, p<0.0001) (Fig 2c) .
In the spatial probe trials after surgery, the GDNF group showed steady learning improvement that was not present in the GFP group (Fig. 2b , probe trials 1-3). The latter rats kept their values of searching time in the correct quadrant at the chance level. By the end of the test-training period, GDNF rats showed values close to the unimpaired control group. The performance differences between GFP-and GDNF-injected rats were significant (ANOVA, F(1,44)=9.869, p=0.0030). No differences of latency to find the hidden platform during the 12 training days were detected between the two rat groups (Fig.   3d ).
The swim speed was not affected by either the surgery or the transgene expression. 
Increase of neurotransmitter levels in the hippocampus after GDNF transduction
Tissue concentration of ChAT, indicative of acetylcholine levels, in selected brain regions of young and aged impaired rats is shown in Fig. 3a (hippocampus areas) and Table 2 (all brain areas assayed). Two-way ANOVA indicated an effect of the cerebral brain region (F(12,180)=14.50, p<0.0001) and of the rat group (F(2,180)=7.56, p=0.0007). By paired ANOVA testing, GDNF rat group was significantly different from GFP and from young rat groups (not shown). In GDNF transduced rats, an increase was detected in the whole CA1 area, as against GFP rats; whereas the ventral part increased also over young rat values.
Cingulate cortex ChAT increased in GDNF rats over the other two groups. There was a decrease in the ventral CA2/3 area of GDNF rats, as against the group of young rats.
Regional brain concentration of dopamine is shown in Fig. 3b (hippocampus areas) and Table 3 (all brain areas assayed) and its metabolites DOPAC and HVA are shown in Table 3 . Two-way ANOVA for brain region and rat group indicated an effect of the brain region factor for the concentration of dopamine and its metabolites (not shown), whereas the rat group factor was significant for both metabolites DOPAC (F(2,321)=12.98, p<0.0001) and HVA (F(2,319)=71.59, p<0.0001). The group effect was significant for dopamine levels when the brain regions were restricted to the hippocampus (F(2,108)=15.81, p<0.0001). In this area, the increase of dopamine shown by the GDNF group was significant in the dorsal CA1 area and in the whole dentate gyrus, as against the group of young rats. A decrease of HVA in both aged GFP and GDNF groups was observed in the dorsal CA1 and CA2/3, cerebral cortical areas and septum. In the caudate region of both aged rat groups there was a decrease in both metabolites, DOPAC and HVA.
Regional brain concentration of serotonin is shown in Fig. 3c (hippocampus areas)
and Table 4 (all brain areas assayed) and its metabolite 5-HIAA is shown in Table 4 . Twoway ANOVA showed an effect of brain region (not shown) and rat group for serotonin and 5-HIAA (F(2,319)=25.45, p<0.0001 and F(2,319)=13.91, p<0.0001, respectively). The GDNF group increased serotonin levels in the whole dorsal hippocampus and in the ventral dentate gyrus more than the GFP group. Both groups of aged rats showed a hippocampal increase of 5-HIAA in the dorsal dentate gyrus and the ventral CA1 area. Serotonin also increased in cingulate and temporal cortical areas and in the caudate of control GFP aged rats, as against to young rats.
Discussion
The over-expression of GDNF in hippocampal astrocytes induced a recovery of spatial cognitive abilities in aged impaired rats as demonstrated by an enhancement of memory retention of the platform location in the test probe trials. This better response in the Morris water maze cannot be attributed to a mere improvement of age-related motor impairment by GDNF. Several studies have shown that GDNF enhances motor function in aged rats and non-human primates, which has been related to dopaminergic induction and regeneration of the nigrostriatal pathway [15, 33, 53, 57, 69] . In the present study, GDNF was over-expressed only in a restricted area of the hippocampus and no changes were induced in the swimming speed. In addition, we found no differences in the latency to escape between the rats expressing GDNF and control rats transduced with GFP during the test assays, where an increase in swimming ability would help the rats to find the platform in a shorter time. Latency to escape to the platform is routinely recorded as an additional spatial learning and memory measure, but its outcome can be affected by external factors. This is not the case with probe trial performance, which is accepted as the most accurate measurement because it requires memory of the precise location of the platform [19, 42] .
Accordingly, in previous studies in our behavioral facilities, the probe trial was established as a reliable result for learning acquisition and retention under our experimental conditions [103] .
The present results confirm the previous report of a significant recovery of cognitively impaired two-year old Fisher 344 rats in the Morris water maze two weeks after an i.c.v.
injection of GDNF [99] . The degree of spatial learning recovery after a GDNF transgene expression in dorsal CA1 astrocytes was similar to that obtained by earlier authors. Spatial learning and memory require the dorsal hippocampus to function [25, 102] , with the CA1 area being particularly crucial for spatial discrimination tasks [90, 120] . In old age, CA1
pyramidal neurons suffer a loss of functional synaptic contacts from the Schaffer collaterals and an alteration in Ca 2+ regulation, both changes leading to plasticity and cognition deficits [59, 105, 116] . The absence of a generalized loss of cells and synapses in the hippocampus and the whole brain in normal aging [61, 85] facilitates amelioration of cognitive decline by neurotrophic action. Both GFR 1 and Ret receptor molecules are highly expressed in the hippocampal neurons of the pyramidal layer of the Ammon's horn [20, 107, 111] . Therefore, GDNF secreted by CA1 transduced astrocytes was able to exert its trophic action on local neurons. Ectopic fiber sprouting is unlikely because GDNF secreted by transduced astrocytes is not or very poorly transported by neurons to distal areas [34] (Mammeri H. et al., unpublished observations). Nevertheless, a histological study should be performed when a long-lasting GDNF gene expression in hippocampus is planned to fully discard the possibility of unwanted effects in projection areas.
Neurochemical changes in cognitively impaired aged rats have been extensively studied in a search for the causes underlying frequent memory loss in older individuals.
Atrophy of acetylcholine containing neurons is considered a hallmark of aging and dementia [115] , but this cholinergic dysfunction occurs within a wider context of neurotransmitter system changes [30, 114] . Cholinergic and monoaminergic neurotransmitter systems are involved in the spatial learning and memory processes in the hippocampus [32, 37, 84, 104, 109] . Hippocampus is a target cholinergic area and no local decrease of ChAT activity was reported in aged rats, confirming our results, whereas ChAT decreases have been found in the cholinergic cell body containing areas of the basal forebrain and striatum in cognitively impaired rats [43] . Hippocampus receives its dopaminergic innervation from the midbrain and is integrated in the mesolimbic system.
Many studies have demonstrated an age-related decline in dopaminergic neurotransmission, mainly in the nigrostriatal system [43, 71, 86] . In addition, decreased density of dopamine receptors D1 to D5 have been reported in several brain areas, including the hippocampus of aged rat and human [4, 55, 63] . We found a widespread decrease of dopamine metabolite HVA in aged rats, indicative of a lower turnover rate. The effect was higher in the caudate, in which both metabolites, DOPAC and HVA, decreased. The role of the serotonergic system in aging impairment has raised controversy. Several authors have reported unchanged or enhanced serotonin levels and turnover in aged rats [43, 71] , while others reported decreases [86] . Confirming the former we found a trend to higher serotonin and 5-HIAA concentrations in several brain regions of the aged rats. As regards serotonin receptors, no age-induced or cognitive-related changes have been reported in 5HT1A
receptor [14, 70] .
GDNF over-expression in CA1 astrocytes induced a local neurotrophic effect.
ChAT activity, indicative of acetylcholine levels, rose in hippocampus. In a study of motor activity enhancement, two weeks of i.c.v. infusion of GDNF induced an increase in ChAT activity in the septum, hippocampus, striatum and cortex of aged rats [69] . This study reported a similar enhancement of ChAT by GDNF or neural growth factor (NGF). The trophic effects of NGF on aged cholinergic neurons have been extensively studied [106, 112] . NGF binds with high affinity to the TrkA receptor, which is mainly located on cholinergic neurons in the basal forebrain nuclei and striatum [62] . A partial recovery of the cognitive abilities in the Morris water maze, similar to that we obtained with GDNF, was reported initially [39, 40] . In subsequent studies, an almost complete reversal was obtained either by a higher dosage through i.c.v. chronic infusion [41] or by NGF-secreting cell implants at the two main cholinergic forebrain cell groups, nucleus basalis magnocellularis and medial septum/diagonal band of Broca (MS/DB) [79] . Although hippocampus function resulted significantly enhanced by astrocyte-secreted GDNF, we did not obtain complete recovery of spatial learning. This could be due to a partial inability of locally expressed GDNF to recover the function of the circuitry entering the hippocampus from cholinergic cell bodies located in the MS/DB. A retrograde signaling of GDNF to these cell bodies [27] may not be enough when functional terminals are already reduced. On the other hand, the complexity of the reciprocal cholinergic connections between CA1 and MS/DB [47, 95] may modulate the functional response. In this regard, ventral CA1 that receives cholinergic afferents from a broader MS/DB area showed a slightly higher ChAT enhancement than the greater GDNF-expressing dorsal CA1 area.
In addition to cholinergic enhancement, GDNF secreted by transduced astrocytes enhanced dopaminergic and serotonergic neurotransmission over control aged rats transduced with GFP. Dopamine and serotonin levels increased without the concentration of their metabolites rising, thus demonstrating a significant neurotransmitter synthesis increase. High variability of dopamine level led to a lack of statistical significance for its increase in the dorsal CA1 area, even though GDNF dopamine value nearly doubled the GFP group value. Given the reduction of dopamine receptor function in the hippocampus discussed above, the increased neurotransmitter levels would help to restore dopaminergic function. On the other hand, the tissue dopamine levels obtained barely could account for an increase of the risk of oxidative damage by dopamine auto-oxidation [21] . However, the presence of hydroxylated adducts in hippocampus should be analyzed whenever a longer therapy is planned. While GDNF increased serotonin levels less than dopamine it similarly enhanced specific synaptic transmission, as long as there was no loss of serotonin receptors due to aging. As discussed above for the cholinergic neurotransmission, GDNF enhancement of the dopaminergic mesencephalic afferents [44] and the serotonergic afferents from the median raphe [83] may not be enough to fully recover the hippocampus functionality. To notice that studies in Parkinson's disease models have demonstrated that GDNF induces a higher functional recovery when acting in the striatum terminals than in the substantia nigra dopaminergic bodies [26, 65] . Therefore, an earlier and sustained therapy of GDNF in the hippocampus would probably result in a better strategy for spatial memory recovery than its delivery to other targets. Nonetheless, testing the GDNF effects on other related brain areas cannot be discarded.
GDNF showed a broad neurotrophic effect and probably also enhanced other neurotransmitters involved in learning and memory such as glutamate and GABA.
GABAergic interneurons, present in the stratum pyramidale and stratum oriens express GFR -1 [107] , lose function with aging [113] . Decrease of NMDA receptor density in the aged CA1 region correlates with spatial learning decline [76] . GDNF has shown trophic effects on GABAergic neurons [45] and neuroprotective effects against NMDA-mediated excitotoxicity [92] . Therefore GDNF may directly enhance these systems or/and counteract the alterations of the interactions between the different brain neurotransmitter systems that contribute to aging deterioration [30, 110] .
The amelioration of senile neurons or damaged dysfunctional neurons in future human therapies may need a continuous supply of trophic factor [93] . Chronic infusion of GDNF through a catheter implanted in the brain has been assayed in Parkinson's patients for periods of up to several years [75] , but may be accompanied by both practical and safety problems. Gene delivery ex vivo or in vivo allows selective local diffusion of the growth factor without undesirable side effects. Strategies in various experimental animal models of neural diseases include the implant of either astrocytes [29, 31, 34] , neural progenitors [2, 7, 9, 66] or fibroblasts [100, 101] engineered to secrete GDNF. However, the advances in the design of viral vectors convert in vivo gene therapy into an attractive strategy for long-term delivery of trophic factors to the nervous system. Neuroprotective effects in experimental models of neurodegenerative diseases have been obtained by direct in vivo transfer of GDNF gene with recombinant adenoviral [1, 11, 24, 31, 68] , adenoassociated [36, 65, 81, 123] and lentiviral vectors [17, 48, 54, 67, 124] . Replication-defective lentiviral vectors are safe and can sustain a strong expression of transgenes for long periods [91] . They can efficiently transduce neurons and glial cells and cause minimal inflammatory and immunological responses [80, 125] . The combination of viral particle pseudotyping and gene promoter facilitates targeting of specific cell types [10, 28] . We constructed a lentiviral vector pseudotyped with Mokola G protein and its gene expression driven by the CMV promoter. This vector showed selectivity for transducing the astrocytes in the hippocampal area of injection.
In conclusion, a short chronic delivery of GDNF in the dorsal CA1 hippocampal astrocytes enhanced local cholinergic, dopaminergic and serotonergic transmission, leading to improved spatial learning and memory performance in cognitively impaired aged rats.
Astrocytes proved to be an appropriated cell type for over-secreting GDNF in gene therapy strategies. Deficiencies were not totally reverted; suggesting that GDNF paracrine action in the CA1 area could be too restricted to obtain complete recovery of the complex behavioral learning task. Finally, lentiviral vectors showed high efficacy, making feasible longer chronic treatment which would probably have a better outcome. Therefore, the present results demonstrated the therapeutic value of lentiviral vectors expressing GDNF transgene in rat age-related cognitive decline. Further studies to explore the therapeutic possibilities of GDNF in human aging and Alzheimer's disease memory loss, are required.
[ Experimental groups: Young, 8-month old rats; GFP, 24-month old cognitively impaired rats transduced with human green fluorescent protein in the dorsal hippocampus CA1; GDNF, 24-month old cognitively impaired rats transduced with human glial cell line derived neurotrophic factor in the dorsal hippocampus CA1. Values are the mean ± SEM of 6-9 animals. Statistics:
(a) significance of GFP or GDNF groups as compared to young rats and (b) significance of GDNF as compared to GFP group; ANOVA followed by Newman-Keules' test at the significance level of p<0.05. in the dorsal hippocampus CA1; GDNF, 24-month old cognitively impaired rats transduced with human glial cell line derived neurotrophic factor in the dorsal hippocampus CA1. Values are the mean ± SEM of 6-9 animals. Statistics: (a) significance of GFP or GDNF groups as compared to young rats; ANOVA followed by Newman-Keules' test at the significance level of p<0.05.
